Moore Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Moore Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$15.1M	–	658
2025 Q4	$15.1M	Sell	50,000 -5,000	-9%	-$1.56M	0.22%	110
2025 Q3	$15.4M	Buy	+55,000	New	+$15M	0.21%	102
2025 Q2	–	Sell	-10,000	Closed	-$2.44M	–	555
2025 Q1	$2.44M	Sell	10,000 -35,000	-78%	-$10.5M	0.05%	246
2024 Q4	$14.8M	Hold	45,000	–	–	0.17%	138
2024 Q3	$15.1M	Buy	+45,000	New	+$14.3M	0.28%	106
2023 Q4	–	Sell	-12,500	Closed	-$4.48M	–	452
2023 Q3	$4.48M	Sell	12,500 -12,500	-50%	-$4.82M	0.08%	177
2023 Q2	$9.48M	Buy	25,000 +23,900	+2,173%	+$9.73M	0.16%	104
2023 Q1	$527K	Buy	+1,100	New	+$515K	0.01%	312

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Moore Capital Management's BIO Position: Q1 2026 in Review

Moore Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 50,000 shares — an estimated $15.1M sold.

Moore Capital Management first reported a position in BIO in Q1 2023 and held it in 8 quarters. The position peaked at $15.4M in Q3 2025. 394 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

Moore Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
Moore Capital Management sold 50,000 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $15.1M.
Moore Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2023 and held it in 8 quarters.
Moore Capital Management's Bio-Rad Laboratories Class A position peaked at $15.4M in Q3 2025.
394 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.